AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
SENSEX 77,139.40
NIFTY 24,079.15
CRUDEOIL 7,722.00
+ 362.00
GOLD 141,385.00
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and…
Zydus and Apollo Hospitals collaborate to enhance access to a multi-cancer blood test for early detection in India.
The merger expands the combined entity’s manufacturing, research, and development capabilities, with a focus on specialty drugs…
Q4 Results Today, 18th May 2026: Find all the latest Q4 results 2026 updates of 63 Moons Technologies, Afcons Infrastructure,…
Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tagrisso after China's IND…
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
